Effects of Tamoxifen on insulin-like growth factors, IGF binding proteins and IGFBP-3 proteolysis in breast cancer patients

Henning Grønbæk, Vasilios Tanos, Dror Meirow, Tamar Peretz, Itamar Raz, Allan Flyvbjerg

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Recently an association between increased serum insulin-like growth factor I (IGF-I) levels and the development of breast cancer was demonstrated. Tamoxifen used in the postoperative treatment of breast cancer patients may exert significant effects on the IGF-I system. Materials and Methods: To examine the effect of Tamoxifen treatment (20 mg/day) on changes in the IGF-I axis in 11 breast cancer patients before and after 4 months of Tamoxifen treatment and compared to 8 healthy subjects. IGF-I, IGF-II, IGFBP-1, IGFBP-2, IGFBP-3 and IGFBP-6 were examined by specific assays. IGFBPs were examined by Western ligand blotting and IGFBP-3 proteolytic activity by specific protease assay. Results: Serum IGF-I was decreased before (63%) and increased during Tamoxifen treatment (60%). Total IGFBP-3 levels measured by IRMA were unchanged, however, intact IGFBP-3 measured by WLB was decreased (58%) before and increased (67%) during Tamoxifen treatment. IGFBP-3 proteolysis was increased before and reduced during treatment. IGFBP-4 and IGFBP-6 were decreased before and increased during Tamoxifen treatment. Conclusion: Significant changes in the IGF system were demonstrated before and during Tamoxifen treatment and may in part be involved in the effects of Tamoxifen treatment in breast cancer patients.

Original languageEnglish
Pages (from-to)2815-2820
Number of pages6
JournalAnticancer Research
Volume23
Issue number3 C
StatePublished - May 2003
Externally publishedYes

Keywords

  • Breast cancer
  • IGF-I
  • IGF-II
  • IGFBP-2
  • IGFBP-3
  • IGFBP-3 proteolysis
  • IGFBP-4
  • IGFBP-6
  • Tamoxifen

Fingerprint

Dive into the research topics of 'Effects of Tamoxifen on insulin-like growth factors, IGF binding proteins and IGFBP-3 proteolysis in breast cancer patients'. Together they form a unique fingerprint.

Cite this